Actinogen Medical Ltd

NEW
FRA:3AC (Australia)  
€ 0.030 (0%) Aug 13
At Loss
P/B:
15.33
Market Cap:
€ 104.84M ($ 121.27M)
Enterprise V:
€ 100.97M ($ 116.80M)
Volume:
0
Avg Vol (2M):
29.48K
Trade In:
Volume:
0
At Loss
Avg Vol (2M):
29.48K

Business Description

Description
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
29.29
Equity-to-Asset
0.79
Debt-to-Equity
0.03
Debt-to-EBITDA
-0.01
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year FCF Growth Rate
15.7
3-Year Book Growth Rate
-18.3

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
68.92
9-Day RSI
64.41
14-Day RSI
61.41
3-1 Month Momentum %
23.33
6-1 Month Momentum %
34.55
12-1 Month Momentum %
157.39

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
4.19
Quick Ratio
4.19
Cash Ratio
3.12

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-18.8
Shareholder Yield %
-1.03

Profitability Rank

Name Current Vs Industry Vs History
ROE %
-106.03
ROA %
-88.79
ROIC %
-778.97
3-Year ROIIC %
2223.48
ROC (Joel Greenblatt) %
-5297.51
ROCE %
-103.83
Moat Score
2

GF Value Rank

Name Current Vs Industry Vs History
Forward PE Ratio
30
PB Ratio
15.33
EV-to-EBIT
-9.3
EV-to-EBITDA
-9.54
EV-to-Forward-EBITDA
-5.03
EV-to-Forward-Revenue
16.31
EV-to-FCF
-10.02
Price-to-Net-Current-Asset-Value 3
Earnings Yield (Greenblatt) %
-10.75
FCF Yield %
-9.61

Financials

FRA:3AC's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Actinogen Medical Ltd Executives

Details

GF Value™

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.003
Beta 2.3063
3-Year Sharpe Ratio 0.48
3-Year Sortino Ratio 1.1
Volatility % 111.85
14-Day RSI 61.41
14-Day ATR (€) 0.002243
20-Day SMA (€) 0.0232
12-1 Month Momentum % 157.39
52-Week Range (€) 0.0115 - 0.045
Shares Outstanding (Mil) 3,719.37

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Actinogen Medical Ltd Filings

Filing Date Document Date Form
No Filing Data

Actinogen Medical Ltd Stock Events

Financials Calendars
Event Date Price (€)
0.5:1 Stock Split 2013-12-03 0.01 (+0.00%)
Show
Entries

Actinogen Medical Ltd Frequently Asked Questions

What is Actinogen Medical Ltd(FRA:3AC)'s stock price today?
The current price of FRA:3AC is €0.03. The 52 week high of FRA:3AC is €0.05 and 52 week low is €0.01.
When is next earnings date of Actinogen Medical Ltd(FRA:3AC)?
The next earnings date of Actinogen Medical Ltd(FRA:3AC) is .
Does Actinogen Medical Ltd(FRA:3AC) pay dividends? If so, how much?
Actinogen Medical Ltd(FRA:3AC) does not pay dividend.

Articles on Actinogen Medical Ltd

No articles.